Abstract: Polycystic ovary syndrome (PCOS) is characterized by elevated levels of androgens, cysts in the ovaries, and irregular periods. Women with PCOS present with additional symptoms, including hirsutism, alopecia, acne, infertility, weight gain, fatigue, depression and mood changes. The present disclosure provides new compounds, salts, compositions and uses thereof in the treatment of PCOS due to elevated adrenal androgens. Further, the present disclosure provides methods for treating PCOS due to elevated adrenal androgens.

Abstract: The present invention provides for cross-neutralizing SARS-COV2 antibodies. The antibodies can be used to treat SARS-CoV2 and variants thereof.

Abstract: Described herein are crystalline composition, methods of making such crystalline composition, pharmaceutical compositions and medicaments comprising such crystalline composition, and methods of using such crystalline composition in the treatment of conditions, diseases, or disorders that would benefit from modulation of Corticotropin-releasing hormone receptor 1 (CRF1).

Abstract: Polycystic ovary syndrome (PCOS) is characterized by elevated levels of androgens, cysts in the ovaries, and irregular periods. Women with PCOS present with additional symptoms, including hirsutism, alopecia, acne, infertility, weight gain, fatigue, depression and mood changes. The present disclosure provides new compounds, salts, compositions and uses thereof in the treatment of PCOS due to elevated adrenal androgens. Further, the present disclosure provides methods for treating PCOS due to elevated adrenal androgens.

Abstract: Described herein are crystalline composition comprising a Corticotropin-releasing hormone receptor 1 (CRF1) antagonist, such as Compound 1: methods of making such crystalline composition, pharmaceutical compositions and medicaments comprising such crystalline composition, and methods of using such crystalline composition in the treatment of conditions, diseases, or disorders that would benefit from modulation of CRF.

Abstract: A computing system receives decrypts learned parameters of a computer-implemented predictive model stored in a computer-readable, non-volatile data store upon instantiation of a model process in volatile memory of the computing system. The predictive model is parameterized by learned parameters that are based upon private data of a user, wherein the learned parameters of the predictive model have been encrypted subsequent to training of the predictive model based upon the private data of the user. The computing system receives a request for a prediction associated with the user. Upon authorizing the request, the computing identifies the predictive model. The computing system, by way of the model process, generates the prediction based upon the request and the predictive model. The computing system outputs the prediction to a computing device associated with the user.

Abstract: The present disclosure provides an in vitro mammalian cell that is genetically modified to provide for enhanced production of adeno-associated virus (AAV) virions. The mammalian cells can be used to produce AAV virions, e.g., recombinant AAV virions that include a heterologous nucleic acid encoding a gene product; the present disclosure thus provides methods for producing an AAV virion, which may be a recombinant AAV virion.

Abstract: Systems and methods are provided for use in implementing access controls to content blocks of a user profile associated with a user. One exemplary system includes an access engine configured to receive an access command from a user, via a communication device, to access the user profile. The access command includes a designation of at least one the content blocks for access by a provider, an identity of the provider, and a duration of the access. The access engine is configured to also modify a permission associated with the designated content block(s) in relation to the provider to permit the access by the provider, and to expose the content block(s) to the provider, thereby granting the access for the provider to the content block(s). The access engine is configured to further terminate the access of the provider to the content block(s) when the duration of the access expires.

Abstract: The present disclosure provides a gene delivery system comprising: a) an R2 retrotransposon R2 polypeptide, or a first nucleic acid comprising a nucleotide sequence encoding the R2 polypeptide; and b) a nucleic acid comprising a heterologous nucleotide sequence encoding one or more heterologous gene products, where the heterologous nucleotide sequence is flanked by an R2 retrotransposon 3? untranslated region (UTR) and an R2 retrotransposon 5? UTR, and where the heterologous nucleotide sequence has a length of at least 200 nucleotides. The present disclosure provides a method of delivering one or more gene products of interest to a eukaryotic cell, the method comprising contacting the cell with the gene delivery vehicle system.

Abstract: The present invention relates to pharmaceutical products comprising fluticasone furoate for use in the treatment of COPD patients, particularly a subgroup of COPD patients that through analysis have been identified as possessing an eosinophil blood count of ?150 cells/?l. The present invention is further directed to methods for treating a patient with COPD which methods include identifying a patient that will respond to treatment and administering a pharmaceutical product of the present invention comprising fluticasone furoate to said patient.

Abstract: A method of charging a cell of a battery includes the steps of: applying a test current to an input terminal of the battery; measuring a voltage output, wherein the voltage output is comprised of a voltage of the cell and a voltage drop, induced by the test current, across an internal impedance of the battery; and applying a charging current to the input terminal of the battery if the measured voltage output is higher than a predetermined voltage, wherein the charging current is greater than the test current.

Abstract: Described herein are platinum-based brush-arm star polymers (Pt-BASPs), or a pharmaceutical composition thereof, for delivery of platinum-based agents, such as oxaliplatin. Also provided are methods and kits involving the Pt-BASPs, or a pharmaceutical composition thereof, for treating proliferative diseases such as cancers (e.g., lung cancer, head-and-neck cancer, esophagus cancer, stomach cancer, breast cancer, pancreas cancer, colorectal cancer, liver cancer, kidney cancer, or prostate cancer) in a subject.

Abstract: Systems and methods are provided for use in implementing access controls to content blocks of a user profile associated with a user. One exemplary system includes an access engine configured to receive an access command from a user, via a communication device, to access the user profile. The access command includes a designation of at least one the content blocks for access by a provider, an identity of the provider, and a duration of the access. The access engine is configured to also modify a permission associated with the designated content block(s) in relation to the provider to permit the access by the provider, and to expose the content block(s) to the provider, thereby granting the access for the provider to the content block(s). The access engine is configured to further terminate the access of the provider to the content block(s) when the duration of the access expires.

Abstract: Historical telemetry data can be used to generate predictions for various classes of data at various aggregates of a system that implements an online service. An anomaly detection process can then be utilized to detect anomalies for a class of data at a selected aggregate. An example anomaly detection process includes receiving telemetry data originating from a plurality of client devices, selecting a class of data from the telemetry data, converting the class of data to a set of metrics, aggregating the set of metrics according to a component of interest to obtain values of aggregated metrics over time for the component of interest, determining a prediction error by comparing the values of the aggregated metrics to a prediction, detecting an anomaly based at least in part on the prediction error, and transmitting an alert message of the anomaly to a receiving entity.

Abstract: Systems and methods are provided for use in implementing access controls to content blocks of a user profile associated with a user. One exemplary system includes an access engine configured to receive an access command from a user, via a communication device, to access the user profile. The access command includes a designation of at least one the content blocks for access by a provider, an identity of the provider, and a duration of the access. The access engine is configured to also modify a permission associated with the designated content block(s) in relation to the provider to permit the access by the provider, and to expose the content block(s) to the provider, thereby granting the access for the provider to the content block(s). The access engine is configured to further terminate the access of the provider to the content block(s) when the duration of the access expires.

Abstract: A delivery device that allows for the sustained release of an agent, particularly useful for the sustained release of a therapeutic agent to limited access regions, such as the posterior chamber of the eye and inner ear. The delivery device is minimally invasive, refillable and may be easily fixed to the treatment area. The delivery device includes a hollow body with an inlet port at its proximal end for insertion of the agent, a reservoir for holding the agent and a delivery mechanism for the sustained delivery of the agent from the reservoir to the patient.

Abstract: A battery protection system, comprising: a first protection circuit configured to detect a battery output voltage value and to disconnect the battery output from a load when the output voltage falls below a first threshold; a second protection circuit configured to detect the battery output voltage value and to disconnect the battery output from the load when the output voltage falls below a second threshold, wherein the first threshold is within a tenth of a volt of the second threshold.

Abstract: A method of charging a cell of a battery includes the steps of: applying a test current to an input terminal of the battery; measuring a voltage output, wherein the voltage output is comprised of a voltage of the cell and a voltage drop, induced by the test current, across an internal impedance of the battery; and applying a charging current to the input terminal of the battery if the measured voltage output is higher than a predetermined voltage, wherein the charging current is greater than the test current.

Abstract: A battery protection system, comprising: a first protection circuit configured to detect a battery output voltage value and to disconnect the battery output from a load when the output voltage falls below a first threshold; a second protection circuit configured to detect the battery output voltage value and to disconnect the battery output from the load when the output voltage falls below a second threshold, wherein the first threshold is within a tenth of a volt of the second threshold.

Abstract: Described herein are platinum-based brush-arm star polymers (Pt-BASPs), or a pharmaceutical composition thereof, for delivery of platinum-based agents, such as oxaliplatin. Also provided are methods and kits involving the Pt-BASPs, or a pharmaceutical composition thereof, for treating proliferative diseases such as cancers (e.g., lung cancer, head-and-neck cancer, esophagus cancer, stomach cancer, breast cancer, pancreas cancer, colorectal cancer, liver cancer, kidney cancer, or prostate cancer) in a subject.